Type 2 Diabetes

Analysis of UK Biobank data combined with a meta-analysis of published literature provides clinicians with an overview of the relationship between type 2 diabetes and accelerated neurocognitive decline.

Using 21 years of follow-up data from more than 3000 patients with prediabetes, results of the DPPOS study demonstrate metformin use and lifestyle intervention reduced the risk of progressing to T2D, but did little to reduce the long-term risk of cardiovascular disease in these patients.

An analysis of data from an ongoing, prospective cohort study in China suggests arterial stiffness, as measured by baPWV, was a better predictor of type 2 diabetes risk than blood pressure measurements.

In this episode of Diabetes Dialogue, hosts Drs. Isaacs and Bellini take a deep dive into the tirzepatide approval, including discussions around the mechanism of action, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of new guidelines for NAFLD.

A systematic review and meta-analysis of 7 trials provide a detailed overview of the reductions in HbA1c and body weight, as well as the safety, of tirzepatide in various doses compared against placebo and other diabetes medications from clinical trials.

Implementation of the USPSTF 2021 and ADA 2022 guidelines would increase screening eligibility by approximately 6 to 7 percentage points.

Diabetic ketoacidosis increased the likelihood of in-hospital mortality by 61%, the likelihood of major adverse cardiovascular events by 56%, and a likelihood of 30-day readmission by 12% among patients hospitalized with heart failure in the US.

An analysis of data from more than 11,000 patients in China suggests arterial stiffness could be a better predictor of type 2 diabetes risk than other traditional risk factors, such as hypertension.

A University of Surrey-led study found patients achieving optimal glucose control in the first 12 months proceeding a T2D diagnosis had a lower risk of cardiovascular events than their counterparts who did not achieve optimal glucose control.

Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.

A retrospective analysis of more than 25k patients with type 2 diabetes details the impact achieving early glycemic control can have on the risk of cardiovascular disease events among these patients.

An analysis of data from the KORA study suggests HSV 2 and CMV seropositivity were independently associated with increased odds of developing prediabetes.

Adolescents with a GLP-1 RA prescription within year of T2D diagnosis were more probable to be in better glycemic control and less probable to be prescribed insulin.

In patients with T2D, adding Gla-300 to GLP-1 RA significantly improved glycemic control without significantly increasing hypoglycemia.

An analysis of data from more than 3500 individuals followed for more than 20 years provides insight into the impact of food insecurity on risk of cardiometabolic conditions, including obesity and type 2 diabetes.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A cross-sectional study of NHANES data suggests lowering BMI thresholds for diabetes screening among racial/ethnic minority patients could improve diabetes diagnosis and lower risk of adverse outcomes.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.

Data from a study presented at the European Congress on Obesity details the effects of adherence to a vegan diet on cardiometabolic health using data obtained from randomized controlled trials assessing the effects of vegan diets as an intervention.

A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.

These data further elucidate the relationship between mental health and diabetic retinopathy.